ClinicalTrials.gg
RecruitingNCT07512167Updated Sep 29, 2026

Tetanus Severity Score for Prediction of Mortality in Manifest Tetanus

An observational study in Tetanus, Manifest, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Ain Shams University · Observational

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Sep 29, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
115
Ages
18 Years and older
Sex
All
01

Study summary

Three scoring systems will be applied to patients suffering from manifest tetanus and will be related to mortality.

Read the detailed description

On admission to the intensive care unit, three scoring systems for tetanus severity will be applied to all patients: the Tetanus Severity Score (TSS), Dakar Score, and Philips Score, and will then be related to the occurrence of in-hospital mortality or survival to hospital discharge.

02

Conditions studied

  • Tetanus, Manifest

Browse trials for

Keywords

  • Tetanus, Tetanus Severity Score
03

In context

Tetanus

318 studies on the registry are indexed under Tetanus; 29 are open to participants now.

This study's planned enrollment of 115 is below the median of 645 across 35 observational studies indexed under Tetanus.

Browse Tetanus studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,950 studies on the registry; 429 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adults of both sexes with manifest tetanus.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (age 18 years old or more).
  • Any sex (male or female), regardless of gender identity.
  • Diagnosis of manifest tetanus according to the WHO criteria (https://www.who.int/news-room/fact-sheets/detail/tetanus), that is the presence of one or both of the following criteria with or without the history of specific wound or injury:

    • Sustained spasm of the facial muscles in which person appears grinning.
    • Painful muscular contractions

Exclusion criteria

Exclusion criteria:

  • Age \< 18 years.
  • Absent criteria of manifest tetanus, as per the WHO criteria (https://www.who.int/news-room/fact-sheets/detail/tetanus).
  • Incomplete medical record with missing data required to calculate the Tetanus Severity Score, Philips Score, or Dakar score.
  • Incomplete medical record with missing data regarding the primary outcome measure (survival to hospital discharge or in-hospital mortality).
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
115 participants (estimated)
Patient registry
No

Groups and cohorts

  • Non-survivors

    Patients who die in hospital

    Diagnostic Test: Tetanus Severity Score (TSS) · Diagnostic Test: Philips Score · Diagnostic Test: Dakar Score

  • Survivors

    Patients who survive to hospital discharge

    Diagnostic Test: Tetanus Severity Score (TSS) · Diagnostic Test: Philips Score · Diagnostic Test: Dakar Score

Interventions

  • Diagnostic testTetanus Severity Score (TSS)

    The Tetanus Severity Score (TSS) is calculated for each patient by the investigator using the required data as documented in the medical records at admission

  • Diagnostic testPhilips Score

    The Philips Score is calculated for each patient by the investigator using the required data as documented in the medical records at admission

  • Diagnostic testDakar Score

    The Dakar Score is calculated for each patient by the investigator using the required data as documented in the medical records at admission

06

What researchers measure

Primary outcomes

  1. Death from any cause.

    Occurrence of death from any cause, assessed from the date of onset of symptoms up to 90 days.

    Time frame: From the date of onset of symptoms until the date of death or date of discharge from the hospital, whichever comes first, assessed up to 90 days.

07

Study locations

1 of 1 sites recruiting
  • Ain Shams University Hospitals & Demanhour Fever Hospital
    Cairo, Cairo Governorate 11341, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — May be provided upon reasonable request from the principal investigator

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Sites
1 site added, 1 site removed
Show site
  • Ain Shams University Hospitals & Demanhour Fever Hospital · Cairo, Egypt
Show 1 removed
  • Ain Shams University Hospitals & Demanhour Fever Hospital · Cairo, Egypt
Sep 29, 2026
Primary completion
Jun 15, 2026→Oct 15, 2026
Sep 29, 2026
Study completion
Jun 15, 2026→Nov 15, 2026
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    1 site added, 1 site removed
    Show site
    • Ain Shams University Hospitals & Demanhour Fever Hospital · Cairo, Egypt
    Show 1 removed
    • Ain Shams University Hospitals & Demanhour Fever Hospital · Cairo, Egypt
    Primary completion Jun 15, 2026→Oct 15, 2026
    Study completion Jun 15, 2026→Nov 15, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07512167
Responsible party
Sameh M. Hakim (Professor of Anesthesiology, Intensive Care and Pain Management, Ain Shams University) — Principal investigator
First posted
Apr 6, 2026
Start date
Apr 15, 2026
Primary completion
Oct 15, 2026 (estimated)
Completion
Nov 15, 2026 (estimated)
Last update
Sep 29, 2026

Study contacts

Sameh M Hakim, MD
Contact
hakimsm@med.asu.edu.eg
+202 26900073
Sameh M Hakim, MD
study director · Ain Shams University Faculty of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion